AstraZeneca to acquire MedImmune for $15.2 billion
The acquisition of MedImmune shall significantly accelerate AstraZeneca's biologics strategy. The combination of MedImmune with AstraZeneca's wholly-owned subsidiary Cambridge Antibody Technology ("CAT") shall create a world-class, fully integrated biologics and vaccines business within the AstraZeneca Group with critical mass in research, development, regulatory, manufacturing and global sales and marketing reach.
The deal is expected to close in June 2007.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.